NSAID use and survival after breast cancer diagnosis in post-menopausal women

Blair, Cindy K.; Sweeney, Carol; Anderson, Kristin E.; Folsom, Aaron R.

doi:10.1007/s10549-006-9277-x

Cited by 74 publications

(95 citation statements)

References 26 publications

(38 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They found a reduced risk of recurrence for current regular (Ն 3 days per week) use of ibuprofen (RR ϭ 0.56; 95% CI, 0.32 to 0.98) but not aspirin (RR ϭ 1.09; 95% CI, 0.74 to 1.61); short follow-up (5 years) may have precluded detecting an association. Blair et al 34 reported a borderline reduced risk of breast cancer death (RR ϭ 0.64; 95% CI, 0.39 to 1.05) for any use of NSAIDs after diagnosis among 591 postmenopausal women with breast cancer in the Iowa Women's Health Study. In that study, aspirin and nonaspirin NSAID use was combined, but use of aspirin only (43%) was considerably more common than use of nonaspirin NSAIDs only (10%) or use of both (27%).…”

Section: Discussionmentioning

confidence: 99%

Aspirin Intake and Survival After Breast Cancer

Holmes

Chen

et al. 2010

JCO

329

261

View full text Add to dashboard Cite

A B S T R A C T PurposeAnimal and in vitro studies suggest that aspirin may inhibit breast cancer metastasis. We studied whether aspirin use among women with breast cancer decreased their risk of death from breast cancer. MethodsThis was a prospective observational study based on responses from 4,164 female registered nurses in the Nurses' Health Study who were diagnosed with stages I, II, or III breast cancer between 1976 and 2002 and were observed until death or June 2006, whichever came first. The main outcome was breast cancer mortality risk according to number of days per week of aspirin use (0, 1, 2 to 5, or 6 to 7 days) first assessed at least 12 months after diagnosis and updated. ResultsThere were 341 breast cancer deaths. Aspirin use was associated with a decreased risk of breast cancer death. The adjusted relative risks (RRs) for 1, 2 to 5, and 6 to 7 days of aspirin use per week compared with no use were 1.07 (95% CI, 0.70 to 1.63), 0.29 (95% CI, 0.16 to 0.52), and 0.36 (95% CI, 0.24 to 0.54), respectively (test for linear trend, P Ͻ .001). This association did not differ appreciably by stage, menopausal status, body mass index, or estrogen receptor status. Results were similar for distant recurrence. The adjusted RRs were 0.91 (95% CI, 0.62 to 1.33), 0.40 (95% CI, 0.24 to 0.65), and 0.57 (95% CI, 0.39 to 0.82; test for trend, P ϭ .03) for 1, 2 to 5, and 6 to 7 days of aspirin use, respectively. ConclusionAmong women living at least 1 year after a breast cancer diagnosis, aspirin use was associated with a decreased risk of distant recurrence and breast cancer death.

show abstract

Section: Discussionmentioning

confidence: 99%

Aspirin Intake and Survival After Breast Cancer

Holmes

Chen

et al. 2010

JCO

329

261

View full text Add to dashboard Cite

show abstract

“…Blair et al [103] examined effects of NSAID intake on survival after invasive breast cancer diagnosis among 591 postmenopausal women ascertained through the Iowa Women's Health Study. Compared to nonusers, women who regularly took an NSAID experienced a 36% reduction in breast cancer mortality and a 43% reduction in allcause mortality after approximately 10 years of followup.…”

Section: Therapeutic Studies Of Nsaids In Human Breast Cancermentioning

confidence: 99%

Cyclooxygenase-2 and the inflammogenesis of breast cancer

Harris

Casto

Harris

2014

WJCO

151

125

View full text Add to dashboard Cite

Cohesive scientific evidence from molecular, animal, and human investigations supports the hypothesis that constitutive overexpression of cyclooxygenase-2 (COX-2) is a ubiquitous driver of mammary carcinogenesis, and reciprocally, that COX-2 blockade has strong potential for breast cancer prevention and therapy. Key findings include the following: (1) COX-2 is constitutively expressed throughout breast cancer development and expression intensifies with stage at detection, cancer progression and metastasis; (2) essential features of mammary carcinogenesis (mutagenesis, mitogenesis, angiogenesis, reduced apoptosis, metastasis and immunosuppression) are linked to COX-2-driven prostaglandin E2 (PGE-2) biosynthesis; (3) upregulation of COX-2 and PGE-2 expression induces transcription of CYP-19 and aromatase-catalyzed estrogen biosynthesis which stimulates unbridled mitogenesis; (4) extrahepatic CYP-1B1 in mammary adipose tissue converts paracrine estrogen to carcinogenic quinones with mutagenic impact; and (5) agents that inhibit COX-2 reduce the risk of breast cancer in women without disease and reduce recurrence risk and mortality in women with breast cancer. Recent sharp increases in global breast cancer incidence and mortality are likely driven by chronic inflammation of mammary adipose and upregulation of COX-2 associated with the obesity pandemic. The totality of evidence clearly supports the supposition that mammary carcinogenesis often evolves as a progressive series of highly specific cellular and molecular changes in response to induction of constitutive overexpression of COX-2 and the prostaglandin cascade in the "inflammogenesis of breast cancer". Key words: Breast Cancer; Cyclooxygenase-2; Nonsteroidal anti-inflammatory drugs; Inflammogenesis; Estrogen; Aromatase Core tip: Mammary carcinogenesis often evolves as a series of highly specific cellular and molecular changes in response to induction of constitutive over-expression of cyclooxygenase-2 (COX-2) and the prostaglandin cascade; reciprocally, agents that block COX-2 have significant value in the chemoprevention and therapy of breast cancer.Harris RE, Casto BC, Harris ZM. Cyclooxygenase-2 and the inflammogenesis of breast cancer. World J Clin Oncol 2014; 5(4): 677-692 Available from: URL: http://www.wjgnet.com/2218-4333/full/v5/ i4/677.htm DOI: http://dx.doi.org/10.5306/wjco.v5.i4.677 INTRODUCTIONMore than a century ago, Virchow et al [1,2] chronic inflammation leads to cancer development by increasing cellular proliferation [3] . Various models of carcinogenesis have been proposed involving inflammatory stimuli and mediators of wound healing [4][5][6] . The recent discovery of the inducible cyclooxygenase-2 (COX-2) gene has rekindled interest in the causal link between inflammation and cancer, and various models of carcinogenesis have been proposed involving inflammatory stimuli and COX-2 expression [7][8][9][10] . The current review synthesizes and interprets the accumulating body of evidence supporting COX-2 driven inflammogenesis as a ge...

show abstract

“…In breast cancer, a number of observational studies have examined associations between aspirin use and disease recurrence or death (4)(5)(6)(7)(8)(9)(10)(11)(12), with three reporting statistically significant reductions in breast cancer-related mortality (5)(6)(7). Most of these studies included women taking aspirin before their breast cancer diagnosis and did not distinguish between pre-and post-diagnostic initiation of exposure in their analyses (5)(6)(7)(8)(9).…”

Section: Introductionmentioning

confidence: 99%

“…Most of these studies included women taking aspirin before their breast cancer diagnosis and did not distinguish between pre-and post-diagnostic initiation of exposure in their analyses (5)(6)(7)(8)(9). Only two previous studies have examined associations between de novo post-diagnostic aspirin use and breast cancer outcomes (11,12).…”

Section: Introductionmentioning

confidence: 99%

De NovoPost-Diagnosis Aspirin Use and Mortality in Women with Stage I–III Breast Cancer

Barron

Murphy

Brown

et al. 2015

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Background: Aspirin use has been associated with significant reductions in breast cancer-related mortality in some observational studies. However, these studies included women who initiated aspirin use before breast cancer diagnosis. It is unclear whether initiating aspirin use after diagnosis is associated with similar reductions in mortality. This study investigates associations between de novo post-diagnostic aspirin use and all cause, breast cancer-specific mortality.Methods: Women, ages 50 to 80, with a diagnosis of stage I-III breast cancer were identified from Ireland's National Cancer Registry (N ¼ 4,540). Initiation of de novo post-diagnostic aspirin use was identified from linked national prescription refill data (N ¼ 764). Adjusted HRs were estimated for associations between de novo aspirin use and all-cause, breast cancer-specific mortality.Results: The median time from diagnosis to aspirin initiation was 1.8 years. The mean number of days' supply of aspirin

show abstract

NSAID use and survival after breast cancer diagnosis in post-menopausal women

Cited by 74 publications

References 26 publications

Aspirin Intake and Survival After Breast Cancer

Aspirin Intake and Survival After Breast Cancer

Cyclooxygenase-2 and the inflammogenesis of breast cancer

De NovoPost-Diagnosis Aspirin Use and Mortality in Women with Stage I–III Breast Cancer

Contact Info

Product

Resources

About